This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ORICPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
by Zacks Equity Research
Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.
NVSPositive Net Change GILDPositive Net Change BAYRYPositive Net Change EXELPositive Net Change
biotechnology earnings medical pharmaceuticals
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
by Zacks Equity Research
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
AZNPositive Net Change BAYRYPositive Net Change AGENNegative Net Change VRNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA
by Zacks Equity Research
RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.
BAYRYPositive Net Change AGENNegative Net Change RAREPositive Net Change VRNAPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Best Momentum Stocks to Buy for July 14th
by Zacks Equity Research
ELDN, KDDIY and PENG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14, 2025.
KDDIYPositive Net Change ELDNPositive Net Change PENGNegative Net Change
biotechnology
Old National Bancorp (ONB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ONBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure
by Zacks Equity Research
BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.
NVSPositive Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Buy Stocks for July 14th
by Zacks Equity Research
WIT, KNOP, PENG, ELDN and KDDIY have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2025.
WITNegative Net Change KDDIYPositive Net Change KNOPNegative Net Change ELDNPositive Net Change PENGNegative Net Change
biotechnology computers transportation
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
by Zacks Equity Research
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
MRKPositive Net Change BAYRYPositive Net Change MRUSNegative Net Change VRNAPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Bayer Wins Hormone-Free Treatment Approval for Women in the UK
by Zacks Equity Research
BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.
NVSPositive Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
by Ekta Bagri
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
BMYPositive Net Change ABBVPositive Net Change
biotechnology biotechs medical pharmaceuticals
JBT Marel (JBTM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
JBTMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, GMS (GMS)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
GMSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
by Zacks Equity Research
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
BAYRYPositive Net Change RAREPositive Net Change VRNAPositive Net Change MREONegative Net Change
biotechnology biotechs medical pharmaceuticals
Shore Bancshares (SHBI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
SHBINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Origin Bancorp (OBK) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
OBKNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump
by Ekta Bagri
Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.
NVSPositive Net Change RHHBYNegative Net Change JNJPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zacks.com featured highlights Yext, Agenus and NCR Voyix
by Zacks Equity Research
VYX, AGEN and YEXT show powerful earnings acceleration for 2H25, signaling strong potential for price momentum ahead.
AGENNegative Net Change YEXTNegative Net Change VYXNegative Net Change
biotechnology
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
by Zacks Equity Research
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
BAYRYPositive Net Change VRNAPositive Net Change RXRXNegative Net Change RLYBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
by Ahan Chakraborty
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Korn/Ferry (KFY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
KFYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Dell Technologies (DELL) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
DELLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, East West Bancorp (EWBC)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
EWBCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Industrial Logistics Properties Trust (ILPT) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
ILPTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines